Alpelisib for lymphatic malformations with a PIK3CA change
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your parent/guardian) can sign consent, and you can agree to participate if you’re asked (assent).
- You can stay at the clinic and follow study visits, exams, and rules for the full schedule.
- Your doctor has confirmed you have symptomatic lymphatic malformation that is not classified as PROS.
- You have a confirmed PIK3CA gene mutation in your body (somatic mutation) before randomization.
- You have at least one measurable lymphatic malformation lesion that the study checks before starting.
- You can take the study medicine by mouth (or through an approved feeding tube).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
This Phase 2 study tests alpelisib in children and adults with MCAP, a condition caused by a specific PIK3CA gene mutation. The goal is to see if the treatment is effective and safe, while carefully monitoring blood sugar and organ function.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
Hear when a new Lymphatic Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.